BioCentury | Jul 25, 2011
Company News

Ildong, Shionogi deal

...Details were not disclosed. Shionogi has rights to pirfenidone from Marnac Inc. (Dallas, Texas) and KDL GmbH...
BioCentury | Jan 5, 2009
Finance

4Q approvals

...Pharma FDA approves Apriso mesalamine for maintenance of remission of ulcerative colitis (UC) Shionogi/InterMune (NASDAQ:ITMN)/Marnac/ KDL GmbH...
BioCentury | Oct 20, 2008
Clinical News

Pirespa pirfenidone regulatory update

...p38 mitogen-activated protein (MAP) kinase inhibitor in Japan, South Korea and Taiwan from Marnac and KDL GmbH...
BioCentury | Oct 17, 2008
Company News

Japan approves Pirespa for IPF

...protein (MAP) kinase inhibitor in Japan, South Korea and Taiwan from Marnac (Dallas, Texas) and KDL...
BioCentury | May 26, 2008
Clinical News

Pirfenidone regulatory update

...p38 mitogen-activated protein (MAP) kinase inhibitor in IPF in January 2009. Last year, Marnac and KDL GmbH...
BioCentury | Jan 7, 2008
Finance

Late stage milestones

...2Q08 Intercytex (LSE:ICX) ICX-PRO Stimulate repair in persistent chronic wounds Submit BLA 2H08 InterMune (NASDAQ:ITMN)/ Marnac/Shionogi/KDL...
BioCentury | Dec 3, 2007
Analyst Picks & Changes

Analyst picks & changes

...$28 from $38 after ITMN bought out its license for pirfenidone from Marnac and co-licensor KDL GmbH...
BioCentury | Dec 3, 2007
Company News

InterMune, KDL GmbH, Marnac deal

...Marnac and KDL sold worldwide rights to patents covering pirfenidone to ITMN for $13.5 million up...
...compound for fibrotic diseases in Japan, South Korea and Taiwan. InterMune Inc. (ITMN), Brisbane, Calif. KDL GmbH...
BioCentury | Mar 26, 2007
Clinical News

Pirfenidone: Phase III expanded

...72 weeks from 60 weeks. Shionogi has Japanese rights to the compound from Marnac and KDL GmbH...
BioCentury | Mar 26, 2007
Clinical News

Pirfenidone regulatory update

...has Japanese rights to the oral p38 mitogen-activated protein (MAP) kinase inhibitor from Marnac and KDL GmbH...
Items per page:
1 - 10 of 19
BioCentury | Jul 25, 2011
Company News

Ildong, Shionogi deal

...Details were not disclosed. Shionogi has rights to pirfenidone from Marnac Inc. (Dallas, Texas) and KDL GmbH...
BioCentury | Jan 5, 2009
Finance

4Q approvals

...Pharma FDA approves Apriso mesalamine for maintenance of remission of ulcerative colitis (UC) Shionogi/InterMune (NASDAQ:ITMN)/Marnac/ KDL GmbH...
BioCentury | Oct 20, 2008
Clinical News

Pirespa pirfenidone regulatory update

...p38 mitogen-activated protein (MAP) kinase inhibitor in Japan, South Korea and Taiwan from Marnac and KDL GmbH...
BioCentury | Oct 17, 2008
Company News

Japan approves Pirespa for IPF

...protein (MAP) kinase inhibitor in Japan, South Korea and Taiwan from Marnac (Dallas, Texas) and KDL...
BioCentury | May 26, 2008
Clinical News

Pirfenidone regulatory update

...p38 mitogen-activated protein (MAP) kinase inhibitor in IPF in January 2009. Last year, Marnac and KDL GmbH...
BioCentury | Jan 7, 2008
Finance

Late stage milestones

...2Q08 Intercytex (LSE:ICX) ICX-PRO Stimulate repair in persistent chronic wounds Submit BLA 2H08 InterMune (NASDAQ:ITMN)/ Marnac/Shionogi/KDL...
BioCentury | Dec 3, 2007
Analyst Picks & Changes

Analyst picks & changes

...$28 from $38 after ITMN bought out its license for pirfenidone from Marnac and co-licensor KDL GmbH...
BioCentury | Dec 3, 2007
Company News

InterMune, KDL GmbH, Marnac deal

...Marnac and KDL sold worldwide rights to patents covering pirfenidone to ITMN for $13.5 million up...
...compound for fibrotic diseases in Japan, South Korea and Taiwan. InterMune Inc. (ITMN), Brisbane, Calif. KDL GmbH...
BioCentury | Mar 26, 2007
Clinical News

Pirfenidone: Phase III expanded

...72 weeks from 60 weeks. Shionogi has Japanese rights to the compound from Marnac and KDL GmbH...
BioCentury | Mar 26, 2007
Clinical News

Pirfenidone regulatory update

...has Japanese rights to the oral p38 mitogen-activated protein (MAP) kinase inhibitor from Marnac and KDL GmbH...
Items per page:
1 - 10 of 19